Table 2.
Bivariate analysis of clinical variables and biological markers in relation to 5-year actual survival (AS) and 5-year actual disease-free survival (DFS)
| Variable | Patients (n = 98), n (%) | Median AS, days | Actual 5-year survival, % | P-value (log-rank test)a | Median DFS, days | Actual 5-year DFS, % | P-value (log-rank test)a |
|---|---|---|---|---|---|---|---|
| Age | 0.108 | 0.829 | |||||
| <62 years | 47 (48%) | 1412 | 42.6% | 420 | 17.0% | ||
| ≥62 years | 51 (52%) | 809 | 26.8% | 382 | 23.5% | ||
| CRS | 0.041 | 0.007 | |||||
| Low | 62 (63%) | 1295 | 38.5% | 568 | 24.2% | ||
| High | 36 (37%) | 794 | 24.3% | 279 | 13.9% | ||
| ED | 0.257 | 0.011 | |||||
| Absent | 87 (89%) | 1239 | 35.3% | 423 | 23.0% | ||
| Present | 11 (11%) | 764 | 27.3% | 297 | 0% | ||
| RM | 0.174 | 0.093 | |||||
| ≤1 mm | 29 (30%) | 850 | 27.6% | 306 | 13.8% | ||
| >1 mm | 69 (70%) | 1295 | 37.2% | 568 | 23.2% | ||
| Grade of metastases | 0.058 | 0.099 | |||||
| I | 27 (28%) | 1318 | 40.4% | 790 | 25.9% | ||
| II or III | 71 (72%) | 914 | 30.6% | 342 | 18.3% | ||
| p53 | 0.195 | 0.317 | |||||
| + | 52 (53%) | 869 | 26.8% | 344 | 19.2% | ||
| − | 46 (47%) | 1460 | 43.1% | 476 | 21.7% | ||
| Ki-67 | 0.159 | 0.166 | |||||
| + | 27 (28%) | 1460 | 48.1% | 790 | 29.6% | ||
| − | 71 (72%) | 881 | 29.3% | 350 | 16.9% | ||
| TS | 0.825 | 0.935 | |||||
| + | 69 (70%) | 1076 | 34.3% | 350 | 23.8% | ||
| − | 29 (30%) | 1274 | 34.5% | 529 | 13.8% |
a
Values in bold are significant at P < 0.05.
CRS, clinical risk score; ED, extrahepatic disease; RM, resection margin; TS, thymidiylate synthase.